drugset / Trial / NCT00289211

C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

NCT00289211 ↗

Phase 3 Completed 83 enrolled Shire
RandomizedParallel-groupDouble-blindTreatment

Summary

The study objective was to determine the safety and efficacy of C1INH-nf for the treatment of acute HAE attacks.

Timeline

Start
2005-03-14
Primary completion
2007-04-13
Completion
2007-04-13

Outcome

Met primary endpoint

registry analysis (unspecified test); C1INH-nf vs Placebo; p = 0.048; Hazard Ratio (HR) 2.048 (95% CI 1.008 to 4.164); Regression, Cox NCT00289211 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject CINRYZE Protein / enzyme biologic 1000 iu Intravenous